The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 15, 2025
Filed:
Jul. 23, 2019
Applicants:
The General Hospital Corporation, Boston, MA (US);
Children's Medical Center Corporation, Boston, MA (US);
Inventors:
Kenneth R. Chien, Cambridge, MA (US);
Leon M. Ptaszek, Newton, MA (US);
Kathy Oi-Lan Lui, Boston, MA (US);
Lior Zangi, Brookline, MA (US);
Wataru Ebina, Boston, MA (US);
Derrick J. Rossi, Roslindale, MA (US);
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/18 (2006.01); A01K 67/0276 (2024.01); A61K 31/4745 (2006.01); A61K 31/513 (2006.01); A61K 31/517 (2006.01); A61K 31/519 (2006.01); A61K 31/555 (2006.01); A61K 31/7068 (2006.01); A61K 31/7115 (2006.01); A61K 33/243 (2019.01); A61K 48/00 (2006.01); A61L 31/10 (2006.01); A61L 31/16 (2006.01); C12N 15/11 (2006.01);
U.S. Cl.
CPC ...
A61K 38/1866 (2013.01); A01K 67/0276 (2013.01); A61K 31/4745 (2013.01); A61K 31/513 (2013.01); A61K 31/517 (2013.01); A61K 31/519 (2013.01); A61K 31/555 (2013.01); A61K 31/7068 (2013.01); A61K 31/7115 (2013.01); A61K 33/243 (2019.01); A61K 48/005 (2013.01); A61L 31/10 (2013.01); A61L 31/16 (2013.01); C12N 15/111 (2013.01); A01K 2207/05 (2013.01); A01K 2217/075 (2013.01); A01K 2227/105 (2013.01); A01K 2267/03 (2013.01); A01K 2267/0393 (2013.01); A61L 2300/258 (2013.01); C12N 2310/11 (2013.01); C12N 2310/14 (2013.01); C12N 2800/30 (2013.01);
Abstract
Aspects of the invention described herein relate to synthetic, modified RNAs and their use in vivo to modulate gene expression. Aspects of the invention further relate to the use of these synthetic, modified RNAs in myocytes, cardiomyocytes, and tumors.